PCDHA11

Across TCGA pan-cancer cohorts, PCDHA11 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated PCDHA11 data layer compared with 10 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PCDHA11 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHA11 expression acts as an unfavorable survival marker, although some lineages such as UVM and KIRC show a favorable association.

LUSC, CESC, and STAD are the cancer types where PCDHA11 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Tertile	II,III,IV	0.471	0.699	<.001	96	view →
CESC	DFS	Tertile	All	0.743	0.876	<.001	72	view →
STAD	OS	Median	All	0.618	0.755	<.001	67	view →
UVM	OS	Tertile	II,III,IV	0.865	0.441	<.001	51	view →
KIRC	DFS	Tertile	All	0.892	0.721	.001	44	view →
KIRP	DFS	Quartile	III,IV	0.632	0.112	.001	42	view →
BLCA	DFS	Median	All	0.183	0.477	.002	30	view →
CHOL	DFS	Median	All	0.135	0.749	.003	25	view →
UCS	DFS	Tertile	IV	0.936	0.306	.017	24	view →
SKCM	DFS	Median	All	0.671	0.567	.003	21	view →
MESO	DFS	Median	III,IV	0.251	0.591	.014	21	view →
HNSC	OS	Quartile	All	0.456	0.709	.004	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

PCDHA11–LUSC (DFS)

Open the LUSC breakdown →